Biochemical markers for risk assessment of seizures in withdrawal syndrome

Withdrawal signs and symptoms are frequently minor but-can develop into a severe, even fatal, condition. Clinical manifestations Of the AWS. begin as soon-as the alcohol consumption is interrupted or diminished after a long period of ingestion of great quantities or alcohol. The clinical manifestations include symptoms of-autonomic hyperactivity, like sweating, tachycardia over 100 bpm, tremor, insomnia, nausea or vomiting, transitive visual, tactile, or hearing hallucinations, Or even psychomotor agitation, anxiety and epileptic crisis. Objective Our aim is to assess the-usefulness of several biochemical,markers and the risk of seizures associated with alcohol withdrawal. Methods This study included 52 inpatients which were assessed with the Ciwa-Ar scale in order to determine the severity of the withdrawal, They were assessed too with the AUDIT stale to determine the risk and abuse of the intake of alcohol. We also Obtained a blood sample to determine the levels of several biomarkers (AST, ALT, GGT, FA, HOM-OCISTEINE, and MCV). We compared the two groups. (patients with seizures Vs. patients without seizure). Student T and Mann Whitney's U tests, and ROC curves were applied. Results We observed a statistical difference between the groups in the levels of alkaline phosphatase the levels Were higher in patients without seizures (148.8 +/- 69.58UI) compared With the patients With seizures (113 +/- 55.1UI). No differences were observed in other groups Conclusion The patients with higher levels of alkaline phosphatase had major risk Of seizures. There were no elevations in the serum level of homocisteine in both groups.